163 related articles for article (PubMed ID: 7521204)
1. Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease.
Brusamolino E; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Bernasconi P; Astori C; Lazzarino M
Ann Oncol; 1994 May; 5(5):427-32. PubMed ID: 7521204
[TBL] [Abstract][Full Text] [Related]
2. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
Brusamolino E; Castelli G; Pagnucco G; Orlandi E; Malagó D; Lazzarino M; Bernasconi C
Haematologica; 1990; 75(4):340-5. PubMed ID: 1703510
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
[TBL] [Abstract][Full Text] [Related]
4. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results.
Viviani S; Bonadonna G; Santoro A; Bonfante V; Zanini M; Devizzi L; Soncini F; Valagussa P
J Clin Oncol; 1996 May; 14(5):1421-30. PubMed ID: 8622055
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
[TBL] [Abstract][Full Text] [Related]
6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
[TBL] [Abstract][Full Text] [Related]
7. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
[TBL] [Abstract][Full Text] [Related]
8. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
[TBL] [Abstract][Full Text] [Related]
9. Is there an effective salvage therapy for advanced Hodgkin's disease?
Canellos GP
Ann Oncol; 1991 Jan; 2 Suppl 1():1-7. PubMed ID: 1710484
[TBL] [Abstract][Full Text] [Related]
10. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
11. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
12. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
13. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience.
Viviani S; Bonadonna G; Santoro A; Zanini M; Zucali R; Negretti E; Valagussa P
Ann Oncol; 1991 Feb; 2 Suppl 2():55-62. PubMed ID: 1710921
[TBL] [Abstract][Full Text] [Related]
14. Late relapses in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy.
Salvagno L; Sorarù M; Aversa SM; Bianco A; Chiarion Sileni V; Pappagallo GL; Fiorentino MV
Ann Oncol; 1993 Sep; 4(8):657-62. PubMed ID: 7694635
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.
Bonfante V; Santoro A; Viviani S; Devizzi L; Balzarotti M; Soncini F; Zanini M; Valagussa P; Bonadonna G
J Clin Oncol; 1997 Feb; 15(2):528-34. PubMed ID: 9053474
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.
Straus DJ; Gaynor JJ; Myers J; Merke DP; Caravelli J; Chapman D; Yahalom J; Clarkson BD
J Clin Oncol; 1990 Jul; 8(7):1173-86. PubMed ID: 1694235
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
[TBL] [Abstract][Full Text] [Related]
19. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
Tannir N; Hagemeister F; Velasquez W; Cabanillas F
J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
